Study shows Ebola vaccine to be safe and effective
The vaccine has proven that it is effective in protecting cynomolgas macaques, a kind of monkey, against a specific strain, EBOV-Makona. The subjects received the vaccine a minimum of seven days before being exposed to the virus. If they received the dose three days before exposure, it only provided partial protection.
The vaccine has genetically engineered vesicular stomatitis virus (VSV) that serves as a carrier to the EBOV gene. VSV is an animal virus, primarily impacting cattle, that has shown effectiveness against several viruses when it is used as an experimental vaccine platform. The macaques showed protective immunity thanks to the vaccine.
Before the study, researchers did not have any information about the way monkeys with VSV-EBOV vaccinations would respond to EBOV-Makona. Currently, EBOV-Makona is present throughout the West African region. This most recent study demonstrates that the immune responses from VSV-EBOV are similar to three viruses.
As of today, the vaccine is now being evaluated in testing involving humans in a worldwide clinical trial.